Latest New Zealand News

Experience Co Limited reports robust Q2 2025 earnings growth, driven by strong revenue gains in skydiving and adventure experiences despite ongoing macroeconomic challenges. The company highlights operational efficiencies and positive cash flow amid a gradual inbound tourism recovery.

Foresta Group Holdings has raised $3.1 million through a convertible note and share placement, while securing exclusive technology licensing and key offtake agreements to propel its flagship New Zealand biomass project.

Singular Health has secured a pivotal MoU with Miami-based Provider Network Solutions and raised $3.7 million to propel its 3Dicom software towards a US commercial pilot, supported by the appointment of esteemed radiologist Dr. Ronny Low.

Entertainment Rewards Ltd has secured a pivotal amendment to its $22.5 million convertible loan, slashing interest costs and extending repayment terms to bolster its financial flexibility.

5G Networks Limited has increased its on-market takeover offer for AuCyber Limited from 11 cents to 13.5 cents per share, marking its final bid ahead of the January 30 deadline.

APA Group has updated its dividend distribution announcement, adjusting for changes in the New Zealand dollar exchange rate and the Dividend Reinvestment Plan share price, with an estimated ordinary dividend of AUD 0.27 per security.

Bathurst Resources reported a first half EBITDA of $27.5 million, surpassing forecasts despite export disruptions, yet lowered its full-year EBITDA guidance to $45-$55 million due to reduced export volumes and softer coal prices.

Fitzroy River Corporation's latest quarterly report reveals a dip in royalty income but highlights progress on major silver and gold projects, alongside strategic moves in energy royalties.

XPON Technologies reports a modest 2% increase in martech revenue and a strong cash position for Q2 FY25, while navigating an 8% decline in annualised recurring revenue amid strategic sales recalibration.

CurveBeam AI has broadened its commercial agreement with Stryker to cover Australia and New Zealand, aiming to accelerate adoption of its HiRise weight bearing CT scanners through targeted surgeon education and promotion.

Dimerix Limited has inked a lucrative licensing agreement with Fuso Pharmaceutical for its kidney disease drug DMX-200 in Japan, while completing recruitment for its pivotal Phase 3 ACTION3 trial.

Pacific Edge announces a two-month delay in the Medicare Local Coverage Determination for its genetic oncology tests, extending the effective date to April 24, 2025. This extension follows the company’s active engagement with US regulatory bodies.